29.20 USD
↘ 1.48 (4.82%)AT CLOSE (03:59 PM EDT)
Quince Therapeutics, Inc. Common Stock
QNCXNASDAQ • USD
29.42
↗ 0.22 (0.75%)
POST MARKET (AS OF 07:31 PM EDT)
Post Market
AS OF 07:31 PM EDT
29.42
↗ 0.22 (0.75%)
Market: CLOSED
Quince Therapeutics, Inc. Common Stock (QNCX) trades at $29.20 per share. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.
Technical & fundamental data as of Oct 2, 2026.
Open?$30.20
High?$31.06
Low?$29.20
Prev. Close?$30.68
Volume?68.4K
Avg. Volume?21.1K
VWAP?$30.23
Rel. Volume?3.25x
Bid / Ask
Bid?$27.00 × 100
Ask?$31.84 × 100
Spread?$4.84
Midpoint?$29.42
Valuation & Ratios
Market Cap?29.7M
Shares Out?1.0M
Float?15.3M
Float %?93.7%
P/E Ratio?N/A
P/B Ratio?0.27
EPS?-$93.99
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
Employees
38
Market Cap
31.2M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2019-05-09
Address
611 GATEWAY BLVD., SUITE 273
SOUTH SAN FRANCISCO, CA 94080
Phone: 415-910-5717
SOUTH SAN FRANCISCO, CA 94080
Phone: 415-910-5717
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?50
Short Sent.?63
Piotroski F-Score?0/9Weak
Altman Z-Score?-6.80Distress
Confidence?50%Low
Short InterestModerate
Short % of Float?0.33%Low
Short Interest?50.3K
Days to Cover?3.0
Free Float15.3M
Avg Daily Volume16.8K
Settlement Date2026-09-15
Financial Health
Current Ratio?14.52Strong
Quick Ratio?14.52Strong
Cash Ratio?13.64Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?0.27CHEAP▾
Peers100
S&P97
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?0.7CHEAP▾
Peers100
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-88.1%WEAK▾
S&P3
ROA?-77.1%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-47001000
Enterprise Value?$-86282760
Fundamentals ratios updated end of day